{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:37:16Z","timestamp":1792103836936,"version":"4.4.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze the clinical and hepatic pathological characteristics of patients with chronic hepatitis B (CHB) alone or with non-alcoholic fatty liver disease (NAFLD), who have normal alanine aminotransferase (ALT) levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The patients with normal ALT levels and pathologically diagnosed CHB alone or in combination with NAFLD were enrolled, the demographic, laboratory, and pathological data were collected and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 391 enrolled CHB patients with normal ALT levels, 107 individuals combined with NAFLD. The incidence of significant liver injury (G and\/or S \u2265 2) in patients with CHB alone was lower significantly than that of patients with CHB and NAFLD (64.08% vs. 78.50%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05), especially by the subgroup analyses in HBeAg positive, male, age &amp;gt; 30 years (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). In all patients, who with negative HBcAg expression had lower HBV DNA levels than those with positive HBcAg expression (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Patients with G and\/or S \u2265 2 had a higher proportion of HBcAg cytoplasm\/cytoplasmic nucleus expression type compared to patients with liver tissue G and S &amp;lt; 2 (32.42% vs. 16.67% in CHB alone, 36.91% vs. 21.74% in CHB + NAFLD, all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Aspartate aminotransferase to ALT ratio index (AAR) demonstrated relatively superior efficacy in diagnosing significant liver fibrosis among patients with CHB and NAFLD, while fibrosis-4 (FIB-4) exhibited superior performance in patients with CHB alone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with normal ALT can still demonstrate significant liver tissue damage. The combination of NAFLD will significantly increase the incidence of significant liver injury in patients with CHB, especially in those who are HBeAg positive, male, over 30 years old.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1626154","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:50:34Z","timestamp":1770879034000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and histopathological features of chronic hepatitis B with normal alanine aminotransferase levels with or without concomitant non-alcoholic fatty liver disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Wencong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingdi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemin","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/j.1478-3231.2011.02491.x","article-title":"Evaluation of normal or minimally elevated alanine transaminase, age and DNA level in predicting liver histological changes in chronic hepatitis B.","volume":"31","author":"Alam","year":"2011","journal-title":"Liver Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s40121-022-00629-5","article-title":"The role of metabolic factors and steatosis in treatment-na\u00efve patients with chronic Hepatitis B and normal alanine aminotransferase.","volume":"11","author":"Diao","year":"2022","journal-title":"Infect Dis Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12072-021-10153-2","article-title":"High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B.","volume":"15","author":"Duan","year":"2021","journal-title":"Hepatol Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"103910","DOI":"10.1016\/j.drudis.2024.103910","article-title":"NAFLD and NASH: etiology, targets and emerging therapies.","volume":"29","author":"Wei","year":"2024","journal-title":"Drug Discov Today."},{"key":"B6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"965548","DOI":"10.3389\/fimmu.2022.965548","article-title":"NAFLD and HBV interplay - related mechanisms underlying liver disease progression.","volume":"13","author":"Tourkochristou","year":"2022","journal-title":"Front Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cgh.2017.09.044","article-title":"Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B.","volume":"16","author":"Seto","year":"2018","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B.","volume":"71","author":"Choi","year":"2020","journal-title":"Hepatology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-o","article-title":"Classification of chronic viral hepatitis: a need for reassessment.","volume":"13","author":"Scheuer","year":"1991","journal-title":"J Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease.","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e3565","DOI":"10.1097\/MD.0000000000003565","article-title":"Relationship between hepatic steatosis and the elevation of aminotransferases in HBV-infected patients With HBe-antigen negativity and a low viral load.","volume":"95","author":"Enomoto","year":"2016","journal-title":"Medicine."},{"key":"B13","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/jgh.13536","article-title":"Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B.","volume":"32","author":"Chan","year":"2017","journal-title":"J Gastroenterol Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"733348","DOI":"10.3389\/fcimb.2021.733348","article-title":"Application of fatty liver inhibition of progression algorithm and steatosis, activity, and fibrosis score to assess the impact of non-alcoholic fatty liver on untreated chronic hepatitis B patients.","volume":"11","author":"Huang","year":"2022","journal-title":"Front Cell Infect Microbiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000518645","article-title":"ALT levels in treatment-naive, chronic hepatitis B patients with concurrent fatty liver disease: a US nationwide study.","volume":"40","author":"Chang","year":"2022","journal-title":"Dig Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of nonalcoholic Steatohepatitis.","volume":"150","author":"Machado","year":"2016","journal-title":"Gastroenterology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s10620-014-3180-9","article-title":"Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors.","volume":"59","author":"Wang","year":"2014","journal-title":"Dig Dis Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s44320-024-00024-x","article-title":"Estrogen receptor activation remodels TEAD1 gene expression to alleviate hepatic steatosis.","volume":"20","author":"Sommerauer","year":"2024","journal-title":"Mol Syst Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"8695196","DOI":"10.1155\/2022\/8695196","article-title":"qHBsAg for the identification of liver histological abnormalities in HBeAg-negative chronic hepatitis B patients with normal and mildly elevated ALT levels.","volume":"2022","author":"Gan","year":"2022","journal-title":"Can J Gastroenterol Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/hep4.1859","article-title":"Presence of liver inflammation in asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis.","volume":"6","author":"Liu","year":"2022","journal-title":"Hepatol Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1069752","DOI":"10.3389\/fimmu.2022.1069752","article-title":"Study on liver histopathology of chronic HBV infected patients with different normal ALT values.","volume":"13","author":"Zeng","year":"2022","journal-title":"Front Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3346\/jkms.2006.21.2.279","article-title":"The degrees of hepatocyte cytoplasmic expression of hepatitis B core antigen correlate with histologic activity of liver disease in the young patients with chronic hepatitis B infection.","volume":"21","author":"Kim","year":"2006","journal-title":"J Korean Med Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"105975","DOI":"10.1016\/j.antiviral.2024.105975","article-title":"Anti-HBc mirrors the activation of HBV-specific CD8+ T cell immune response and exhibits a direct effect on HBV control.","volume":"230","author":"Ye","year":"2024","journal-title":"Antiviral Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/jcm13041046","article-title":"Non-invasive assessment of liver fibrosis in hepatitis B patients.","volume":"13","author":"Bera","year":"2024","journal-title":"J Clin Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.12998\/wjcc.v7.i15.2022","article-title":"Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis.","volume":"7","author":"Xu","year":"2019","journal-title":"World J Clin Cases."},{"key":"B26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.gastrohep.2018.12.004","article-title":"Comparison of non-invasive models for predicting liver damage in chronic hepatitis B patients.","volume":"42","author":"Yu","year":"2019","journal-title":"Gastroenterol Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/diagnostics11010098","article-title":"Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease.","volume":"11","author":"Ballestri","year":"2021","journal-title":"Diagnostics."},{"key":"B28","doi-asserted-by":"publisher","first-page":"10108","DOI":"10.3748\/wjg.v20.i29.10108","article-title":"Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.","volume":"20","author":"Kessoku","year":"2014","journal-title":"World J Gastroenterol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"100350","DOI":"10.1016\/j.jhepr.2021.10035","article-title":"Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.","volume":"3","author":"van Kleef","year":"2021","journal-title":"JHEP Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3350\/cmh.2022.0422","article-title":"Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: challenges and perspectives.","volume":"29","author":"Huang","year":"2023","journal-title":"Clin Mol Hepatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1626154\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:50:34Z","timestamp":1770879034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1626154\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":30,"alternative-id":["10.3389\/fmed.2026.1626154"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1626154","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1626154"}}